304 related articles for article (PubMed ID: 30890551)
1. Sex Hormones and Anticancer Immunity.
Özdemir BC; Dotto GP
Clin Cancer Res; 2019 Aug; 25(15):4603-4610. PubMed ID: 30890551
[TBL] [Abstract][Full Text] [Related]
2. Sex Hormones in Breast Cancer Immunity.
Hargrove-Wiley E; Fingleton B
Cancer Res; 2023 Jan; 83(1):12-19. PubMed ID: 36279153
[TBL] [Abstract][Full Text] [Related]
3. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
[TBL] [Abstract][Full Text] [Related]
4. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
[TBL] [Abstract][Full Text] [Related]
5. Sex steroids in the tumor microenvironment and prostate cancer progression.
Boibessot C; Toren P
Endocr Relat Cancer; 2018 Mar; 25(3):R179-R196. PubMed ID: 29317479
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer: any room left for immunotherapies?
Baxevanis CN; Fortis SP; Perez SA
Immunotherapy; 2019 Feb; 11(2):69-74. PubMed ID: 30727800
[No Abstract] [Full Text] [Related]
7. Immune response in prostate cancer.
Cracco CM; Terrone C; Porpiglia F; Scarpa RM
Minerva Urol Nefrol; 2005 Dec; 57(4):301-11. PubMed ID: 16247351
[TBL] [Abstract][Full Text] [Related]
8. Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.
Jordan VC; Fan P; Abderrahman B; Maximov PY; Hawsawi YM; Bhattacharya P; Pokharel N
Discov Med; 2016 May; 21(117):411-27. PubMed ID: 27355337
[TBL] [Abstract][Full Text] [Related]
9. Why is immunotherapy effective (or not) in patients with MSI/MMRD tumors?
Nebot-Bral L; Coutzac C; Kannouche PL; Chaput N
Bull Cancer; 2019 Feb; 106(2):105-113. PubMed ID: 30342749
[TBL] [Abstract][Full Text] [Related]
10. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
11. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
12. Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
Flynn MJ; Larkin JMG
Expert Opin Pharmacother; 2017 Oct; 18(14):1477-1490. PubMed ID: 28820000
[TBL] [Abstract][Full Text] [Related]
13. Juxtacrine Signaling Inhibits Antitumor Immunity by Upregulating PD-L1 Expression.
Yang WH; Cha JH; Xia W; Lee HH; Chan LC; Wang YN; Hsu JL; Ren G; Hung MC
Cancer Res; 2018 Jul; 78(14):3761-3768. PubMed ID: 29789418
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application.
Mandai M; Hamanishi J; Abiko K; Matsumura N; Baba T; Konishi I
Int J Clin Oncol; 2016 Jun; 21(3):456-61. PubMed ID: 26968587
[TBL] [Abstract][Full Text] [Related]
15. [Hormones and lupus].
Gompel A; Pelissier C; Kuttenn F; Mauvais-Jarvis P
Rev Med Interne; 1985 Dec; 6(5):543-52. PubMed ID: 3914021
[TBL] [Abstract][Full Text] [Related]
16. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer.
Zhou ZQ; Zhao JJ; Pan QZ; Chen CL; Liu Y; Tang Y; Zhu Q; Weng DS; Xia JC
J Immunother Cancer; 2019 Aug; 7(1):228. PubMed ID: 31455411
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer.
Shien K; Papadimitrakopoulou VA; Wistuba II
Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919
[TBL] [Abstract][Full Text] [Related]
19. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for the treatment of breast cancer.
Ernst B; Anderson KS
Curr Oncol Rep; 2015 Feb; 17(2):5. PubMed ID: 25677118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
